We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Strong Growth Aid INNV's Q3 Earnings Amid Margin Seasonality?
Read MoreHide Full Article
Key Takeaways
InnovAge is set to report Q3 fiscal 2026 results, with EPS expected to jump 175% year over year.
INNV's growth is driven by membership gains, Medicaid reinstatements, and higher capitation rates.
INNV faces seasonal cost pressures and fading tailwinds, with margins likely to moderate in the near term.
InnovAge (INNV - Free Report) is scheduled to release third-quarter fiscal 2026 results on May 05, after market close. In the last reported quarter, the company delivered an earnings surprise of 100.00%.
The company appears to have entered the second half of fiscal 2026 with strong operational momentum and improving financial visibility. While membership growth is likely to have remained solid, supported by successful Medicaid reinstatements and steady enrollment trends, some normalization is expected as prior tailwinds fade. At the same time, medical cost management and operational efficiencies are likely to have remained favorable, though seasonal pressures such as higher inpatient utilization could weigh modestly on margins.
So far this year, INNV’s shares have surged 60.3% against the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period.
Image Source: Zacks Investment Research
Q3 Estimates
The Zacks Consensus Estimate for earnings is pegged at 6 cents per share, indicating an increase of 175% year over year.
The consensus mark for revenues is pinned at $234.5 million, implying growth of 7.5% from the prior-year reported figure.
Factors to Note
InnovAge’s upcoming quarterly performance is likely to have reflected continued operational momentum, though some normalization in margins and seasonal pressures could temper near-term upside following a strong first half. The company recently delivered double-digit revenue growth and a sharp improvement in profitability, driven by better execution across its PACE (Program of All-Inclusive Care for the Elderly) model and favorable rate dynamics.
At the consolidated level, revenue growth is expected to have remained healthy, supported by membership expansion and higher capitation rates. Recent strength has been aided by the successful reinstatement of participants who had previously lost Medicaid coverage, which boosted member months and reduced revenue reserves. However, as this tailwind normalizes, growth may increasingly depend on organic enrollment gains and retention improvements. Additionally, while Medicaid rates have been slightly favorable, the broader reimbursement environment remains subject to policy variability, particularly around Medicare risk adjustments.
From a cost perspective, medical cost management has emerged as a key driver of margin expansion. The company has demonstrated improved control over inpatient and skilled nursing utilization, alongside benefits from in-house pharmacy operations. These efficiencies are likely to have persisted, though seasonal factors — such as higher flu incidence and elevated inpatient admissions — could pressure medical costs in the near term.
Operationally, center-level productivity and SG&A discipline have improved meaningfully through restructuring and better workforce management, which is likely to have contributed to margin expansion. Still, management has indicated that the third quarter is likely to be typically softer due to enrollment seasonality and cost pressures, suggesting some moderation in profitability before reacceleration later in the year.
The census growth, participant retention, and continued improvements in revenue integrity will be critical. Initiatives around patient experience and reducing clinical variability could support longer-term growth and margin durability, though these benefits are likely to accrue gradually.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for INNV. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical (MBOT - Free Report) has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Can Strong Growth Aid INNV's Q3 Earnings Amid Margin Seasonality?
Key Takeaways
InnovAge (INNV - Free Report) is scheduled to release third-quarter fiscal 2026 results on May 05, after market close. In the last reported quarter, the company delivered an earnings surprise of 100.00%.
The company appears to have entered the second half of fiscal 2026 with strong operational momentum and improving financial visibility. While membership growth is likely to have remained solid, supported by successful Medicaid reinstatements and steady enrollment trends, some normalization is expected as prior tailwinds fade. At the same time, medical cost management and operational efficiencies are likely to have remained favorable, though seasonal pressures such as higher inpatient utilization could weigh modestly on margins.
So far this year, INNV’s shares have surged 60.3% against the industry’s fall of 11.6%. The S&P Index has gained 6.5% in the same period.
Image Source: Zacks Investment Research
Q3 Estimates
The Zacks Consensus Estimate for earnings is pegged at 6 cents per share, indicating an increase of 175% year over year.
The consensus mark for revenues is pinned at $234.5 million, implying growth of 7.5% from the prior-year reported figure.
Factors to Note
InnovAge’s upcoming quarterly performance is likely to have reflected continued operational momentum, though some normalization in margins and seasonal pressures could temper near-term upside following a strong first half. The company recently delivered double-digit revenue growth and a sharp improvement in profitability, driven by better execution across its PACE (Program of All-Inclusive Care for the Elderly) model and favorable rate dynamics.
At the consolidated level, revenue growth is expected to have remained healthy, supported by membership expansion and higher capitation rates. Recent strength has been aided by the successful reinstatement of participants who had previously lost Medicaid coverage, which boosted member months and reduced revenue reserves. However, as this tailwind normalizes, growth may increasingly depend on organic enrollment gains and retention improvements. Additionally, while Medicaid rates have been slightly favorable, the broader reimbursement environment remains subject to policy variability, particularly around Medicare risk adjustments.
From a cost perspective, medical cost management has emerged as a key driver of margin expansion. The company has demonstrated improved control over inpatient and skilled nursing utilization, alongside benefits from in-house pharmacy operations. These efficiencies are likely to have persisted, though seasonal factors — such as higher flu incidence and elevated inpatient admissions — could pressure medical costs in the near term.
Operationally, center-level productivity and SG&A discipline have improved meaningfully through restructuring and better workforce management, which is likely to have contributed to margin expansion. Still, management has indicated that the third quarter is likely to be typically softer due to enrollment seasonality and cost pressures, suggesting some moderation in profitability before reacceleration later in the year.
The census growth, participant retention, and continued improvements in revenue integrity will be critical. Initiatives around patient experience and reducing clinical variability could support longer-term growth and margin durability, though these benefits are likely to accrue gradually.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for INNV. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3 at present.
InnovAge Holding Corp. Price and EPS Surprise
InnovAge Holding Corp. price-eps-surprise | InnovAge Holding Corp. Quote
Stocks Worth a Look
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Microbot Medical (MBOT - Free Report) has an Earnings ESP of +8.70% and a Zacks Rank of 2 at present.
MBOT’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 7.53%. The Zacks Consensus Estimate for MBOT’s first-quarter loss per share implies no change from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.28% and a Zacks Rank #3 at present. The company is slated to release first-quarter 2026 results on May 5.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 2.14%. The Zacks Consensus Estimate for HSIC’s first-quarter EPS indicates an improvement of 4.4% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.77% and a Zacks Rank of 3 at present. The company is slated to release first-quarter 2026 results on May 5.
IDXX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.11%. The Zacks Consensus Estimate for IDXX’s first-quarter EPS indicates a gain 15.5% from the year-ago reported figure.